205 related articles for article (PubMed ID: 38710296)
21. Theranostics in Brain Tumors.
Shooli H; Nemati R; Ahmadzadehfar H; Aboian M; Jafari E; Jokar N; Nabipour I; Dadgar H; Gholamrezanezhad A; Larvie M; Assadi M
PET Clin; 2021 Jul; 16(3):397-418. PubMed ID: 34053584
[TBL] [Abstract][Full Text] [Related]
22. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
23. Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy.
Jo SD; Ku SH; Won YY; Kim SH; Kwon IC
Theranostics; 2016; 6(9):1362-77. PubMed ID: 27375785
[TBL] [Abstract][Full Text] [Related]
24. Recent Advances in Theranostic Applications of Nanomaterials in Cancer.
Ahmed F; Khan MA; Haider N; Ahmad MZ; Ahmad J
Curr Pharm Des; 2022; 28(2):133-150. PubMed ID: 34530703
[TBL] [Abstract][Full Text] [Related]
25. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
[TBL] [Abstract][Full Text] [Related]
26. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Kulkarni HR; Singh A; Langbein T; Schuchardt C; Mueller D; Zhang J; Lehmann C; Baum RP
Br J Radiol; 2018 Nov; 91(1091):20180308. PubMed ID: 29762048
[TBL] [Abstract][Full Text] [Related]
27. [PET/CT: Molecular Imaging and Theranostics for Radionuclide Therapy].
Derlin T; Bengel FM
Pneumologie; 2017 Jan; 71(1):48-62. PubMed ID: 28114710
[No Abstract] [Full Text] [Related]
28. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.
Bolcaen J; Kleynhans J; Nair S; Verhoeven J; Goethals I; Sathekge M; Vandevoorde C; Ebenhan T
Theranostics; 2021; 11(16):7911-7947. PubMed ID: 34335972
[TBL] [Abstract][Full Text] [Related]
29. Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.
Zhu L; Staley C; Kooby D; El-Rays B; Mao H; Yang L
Cancer Lett; 2017 Mar; 388():139-148. PubMed ID: 27916607
[TBL] [Abstract][Full Text] [Related]
30. Theranostic Applications of Nanomaterials in Alzheimer's Disease: A Multifunctional Approach.
Tripathi P; Shukla P; Bieberich E
Curr Pharm Des; 2022; 28(2):116-132. PubMed ID: 34809540
[TBL] [Abstract][Full Text] [Related]
31. Theranostics - a sure cure for cancer after 100 years?
Song Y; Zou J; Castellanos EA; Matsuura N; Ronald JA; Shuhendler A; Weber WA; Gilad AA; Müller C; Witney TH; Chen X
Theranostics; 2024; 14(6):2464-2488. PubMed ID: 38646648
[TBL] [Abstract][Full Text] [Related]
32. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.
Zhu L; Zhou Z; Mao H; Yang L
Nanomedicine (Lond); 2017 Jan; 12(1):73-87. PubMed ID: 27876448
[TBL] [Abstract][Full Text] [Related]
33. Advances in Radioligand Theranostics in Oncology.
Lawal IO; Abubakar SO; Ndlovu H; Mokoala KMG; More SS; Sathekge MM
Mol Diagn Ther; 2024 May; 28(3):265-289. PubMed ID: 38555542
[TBL] [Abstract][Full Text] [Related]
34. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
35. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.
Miller C; Rousseau J; Ramogida CF; Celler A; Rahmim A; Uribe CF
Theranostics; 2022; 12(1):232-259. PubMed ID: 34987643
[TBL] [Abstract][Full Text] [Related]
36. Application and Importance of Theranostics in the Diagnosis and Treatment of Cancer.
Jeyamogan S; Khan NA; Siddiqui R
Arch Med Res; 2021 Feb; 52(2):131-142. PubMed ID: 33423803
[TBL] [Abstract][Full Text] [Related]
37. Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology.
Brastianos P; Davies MA; Margolin K; Yu HA
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e59-e69. PubMed ID: 31099629
[TBL] [Abstract][Full Text] [Related]
38. An introduction to the clinical practice of theranostics in oncology.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
[TBL] [Abstract][Full Text] [Related]
39. Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.
Chen Z; Krishnamachary B; Pachecho-Torres J; Penet MF; Bhujwalla ZM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1595. PubMed ID: 31642207
[TBL] [Abstract][Full Text] [Related]
40. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
